Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging

John C. Stendahl*1, Jennifer M. Kwan*1, Darko Pucar2, and Mehran M. Sadeghi1,3

1Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut; 2Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut; and 3Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) different classes of targets used for molecular imaging of inflammation; (2) emerging radiotracers for cardiovascular inflammation and thrombosis imaging; and (3) emerging radiotracers for cardiovascular fibrosis, calcification and amyloidosis imaging.

Financial Disclosure: This work was supported by grants from NIH (R01AG065917 and R01HL138567) and the Department of Veterans Affairs (0-BX004038). Dr. Pucar is a board member, officer, or trustee for the Society of Nuclear Medicine and Molecular Imaging, a consultant or advisor for Coher Health, an employee of Yale University, an investigator for the National Institutes of Health, and a meeting participant or lecturer for Telix Pharmaceuticals. Dr. Kwan is a board member, officer, or trustee for the American Physician Scientists Association. Dr. Sadeghi is an inventor on Yale University MMP and fibrosis tracer patent applications, and a member of the Board of Directors of the American Society of Nuclear Cardiology. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest.

CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmilearningcenter.org) through July 2025.

Cardiovascular imaging is evolving in response to systemwide trends toward molecular characterization and personalized therapies. The development of new radiotracers for PET and SPECT imaging is central to addressing the numerous unmet diagnostic needs that relate to these changes. In this 2-part review, we discuss select radiotracers that may help address key unmet clinical diagnostic needs in cardiovascular medicine. Part 1 examined key technical considerations pertaining to cardiovascular radiotracer development and reviewed emerging radiotracers for perfusion and neuronal imaging. Part 2 covers radiotracers for imaging cardiovascular inflammation, thrombosis, fibrosis, calcification, and amyloidosis. These radiotracers have the potential to address several unmet needs related to the risk stratification of atheroma, detection of thrombi, and the diagnosis, characterization, and risk stratification of cardiomyopathies. In the first section, we discuss radiotracers targeting various aspects of inflammatory responses in pathologies such as myocardial infarction, myocarditis, sarcoidosis, atherosclerosis, and vasculitis. In a subsequent section, we discuss radiotracers for the detection of systemic and device-related thrombi, such as those targeting fibrin (e.g., 64Cu-labeled fibrin-binding probe 8). We also cover emerging radiotracers for the imaging of cardiovascular fibrosis, such as those targeting fibroblast activation protein (e.g., 68Ga-fibroblast activation protein inhibitor). Lastly, we briefly review radiotracers for imaging of cardiovascular calcification (18F-NaF) and amyloidosis (e.g., 99mTc-pyrophosphate and 18F-florbetapir).

Key Words: molecular imaging; fibrosis; inflammation; radiotracers; thrombosis

Received Nov. 14, 2021; revision accepted Feb. 22, 2022.

For correspondence or reprints, contact Mehran M. Sadeghi (mehran.sadeghi@yale.edu).

*Contributed equally to this work.

COPYRIGHT © 2022 by the Society of Nuclear Medicine and Molecular Imaging.

DOI: 10.2967/jnumed.121.283507

T here is a growing trend in cardiovascular medicine toward molecular characterization and personalized therapies. The development of improved radiotracers for PET and SPECT imaging is central to addressing the clinical needs of the evolving clinical landscape. This 2-part review examines key technical considerations pertaining to cardiovascular radiotracer development and discusses emerging radiotracers in important areas of cardiovascular imaging. Technical considerations and radiotracers for cardiovascular perfusion and neuronal imaging were discussed in part 1. Part 2 covers emerging radiotracers for imaging cardiovascular inflammation, fibrosis, thrombosis, calcification, and amyloidosis (Table 1).

RADIOTRACERS FOR IMAGING CARDIOVASCULAR INFLAMMATION

Inflammation promotes atherosclerosis, mediates cardiomyopathy, and plays central roles in myocarditis and sarcoidosis (1–3). In atherosclerosis, enhanced inflammation is considered a marker of plaque vulnerability and can lead to plaque rupture and acute myocardial infarction (MI) (1). Myocardial injury promotes both focal and systemic inflammation, where different subsets of immune cells have distinctive roles in tissue damage and repair. Early on, the recruitment of neutrophils and inflammatory monocytes (which differentiate into an M1-like proinflammatory phenotype) promotes tissue damage. After the initial phase of injury, tissue repair is supported by the transition to cells with an M2-like, inflammation-resolving phenotype (4). Regulatory T cells are critical to this transition (5). Accordingly, tissue
inflammation plays a dual role after myocardial injury, and dysregulation of this process can lead to cardiomyopathy and heart failure. T lymphocytes also play major roles in autoimmune and viral myocarditis (2), as well as in sarcoidosis, where the secretion of cytokines such as interferon γ is crucial to granuloma formation (6). Chemokines and chemokine receptors, such as chemokine receptor type 2 (CCR2) and CXC chemokine receptor type 4 (CXCR4), mediate the recruitment of monocytes and other inflammatory cells (7). These inflammatory cells are sources of proteases that modulate inflammation and tissue remodeling, including cathepsins and matrix metalloproteases (MMPs) (8,9). Dysregulated protease activation can destabilize atheroma and contribute to adverse myocardial remodeling (8,10).

Cardiovascular inflammation in pathologies such as vasculitis and sarcoidosis has traditionally been imaged with 18F-FDG PET (11,12). 18F-FDG uptake in inflammation is attributed to the high metabolic activity of immune cells, such as macrophages and neutrophils (13,14). One challenge with 18F-FDG PET for imaging of cardiovascular inflammation is its lack of specificity, which, for instance, mandates dietary interventions to suppress myocardial uptake. In addition, 18F-FDG cannot distinguish between subsets of inflammatory cells that characterize the different stages of the

<table>
<thead>
<tr>
<th>Application</th>
<th>Radiotracer</th>
<th>Mechanism/target</th>
<th>Status</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inflammation</td>
<td>18F-FDG</td>
<td>Glucose analog</td>
<td>FDA-approved for myocardial viability imaging</td>
<td>(11,12)</td>
</tr>
<tr>
<td></td>
<td>11C-PK11195</td>
<td>Mitochondrial TSPO</td>
<td>Initial clinical evaluations</td>
<td>(17,18)</td>
</tr>
<tr>
<td></td>
<td>11C-PBR28</td>
<td>TSPO</td>
<td>Initial clinical evaluations</td>
<td>(19,21)</td>
</tr>
<tr>
<td></td>
<td>18F-PBR06</td>
<td>TSPO</td>
<td>Initial clinical evaluations</td>
<td>(19)</td>
</tr>
<tr>
<td></td>
<td>18F-GE180</td>
<td>TSPO</td>
<td>Initial clinical evaluations</td>
<td>(20)</td>
</tr>
<tr>
<td></td>
<td>68Ga-DOTATATE</td>
<td>SSTR</td>
<td>FDA-approved for neuroendocrine tumor imaging</td>
<td>(23)</td>
</tr>
<tr>
<td></td>
<td>68Ga-DOTATOC</td>
<td>SSTR</td>
<td>FDA-approved for neuroendocrine tumor imaging</td>
<td>(26)</td>
</tr>
<tr>
<td></td>
<td>68Ga64Cu-DOTA-ECL1i</td>
<td>CCR2</td>
<td>Initial clinical evaluations</td>
<td>(31,32)</td>
</tr>
<tr>
<td></td>
<td>64Cu-DOTA-vMIP-II</td>
<td>Chemokine receptors (broad)</td>
<td>Preclinical</td>
<td>(33)</td>
</tr>
<tr>
<td></td>
<td>66Ga-pentixafor</td>
<td>CXCR4</td>
<td>Initial clinical evaluations</td>
<td>(30)</td>
</tr>
<tr>
<td></td>
<td>99mTc-RP805</td>
<td>MMPs</td>
<td>Preclinical</td>
<td>(38)</td>
</tr>
<tr>
<td></td>
<td>11In-RP782</td>
<td>MMPs</td>
<td>Preclinical</td>
<td>(35,36)</td>
</tr>
<tr>
<td></td>
<td>99mTc-RYM1</td>
<td>MMPs</td>
<td>Preclinical</td>
<td>(38)</td>
</tr>
<tr>
<td></td>
<td>89Zr-DFO-anti-CD3</td>
<td>CD3 + T cells</td>
<td>Preclinical</td>
<td>(44)</td>
</tr>
<tr>
<td></td>
<td>89Zr-DFO-CD4</td>
<td>CD4 + T cells</td>
<td>Preclinical</td>
<td>(45)</td>
</tr>
<tr>
<td></td>
<td>89Zr-DFO-CD8a</td>
<td>CD8 + T cells</td>
<td>Preclinical</td>
<td>(45)</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>64Cu-FBP8</td>
<td>Fibrin</td>
<td>Initial clinical evaluations</td>
<td>(49,50)</td>
</tr>
<tr>
<td></td>
<td>18F-GP1</td>
<td>Glycoprotein Ilb/Illa</td>
<td>Initial clinical evaluations</td>
<td>(54,55)</td>
</tr>
<tr>
<td></td>
<td>18F-ENC2015</td>
<td>Factor Xllia substrate</td>
<td>Preclinical</td>
<td>(58)</td>
</tr>
<tr>
<td>Fibrosis</td>
<td>68Ga-FAPI</td>
<td>FAP</td>
<td>Initial clinical evaluations</td>
<td>(67,68)</td>
</tr>
<tr>
<td></td>
<td>99mTc-collagelin, 68Ga-collagelin</td>
<td>Type I and III collagen</td>
<td>Preclinical</td>
<td>(70,71)</td>
</tr>
<tr>
<td></td>
<td>68Ga-CBP7, 68Ga-CBP8</td>
<td>Type I collagen</td>
<td>Initial clinical evaluations</td>
<td>(72,73)</td>
</tr>
<tr>
<td>Calciﬁcation</td>
<td>18F-NaF</td>
<td>Hydroxyapatite</td>
<td>FDA-approved for bone imaging</td>
<td>(74–77)</td>
</tr>
<tr>
<td>Amyloidosis</td>
<td>99mTc-pyrophosphate, 99mTc-HMDP, 99mTc-DPD</td>
<td>Transthyretin amyloid fibrils</td>
<td>Expanding clinical use*</td>
<td>(82)</td>
</tr>
<tr>
<td></td>
<td>11C-Pittsburgh compound B</td>
<td>Amyloid fibrils (AL, ATTR)</td>
<td>Initial clinical evaluations</td>
<td>(83)</td>
</tr>
<tr>
<td></td>
<td>18F-florbetapir, 18F-flutemetamol, 18F-florbetaben</td>
<td>Amyloid fibrils (AL, ATTR)</td>
<td>FDA-approved for imaging brain β-amyloid plaques</td>
<td>(84–86)</td>
</tr>
</tbody>
</table>

*99mTc-pyrophosphate is FDA-approved for imaging of bone, acute MI, and blood pool.
inflammatory process and play distinct roles in cardiovascular disease. Addressing this limitation by targeting more specific molecular signatures may help to better define disease stages, monitor disease progression, guide the selection of therapeutic interventions, and follow responses to treatment. The availability of highly specific tracers, potentially in the setting of multitracer PET and SPECT imaging to fine-tune diagnoses, will be critical for expanded diagnostic and theranostic applications in cardiovascular inflammation. The potential of dual-tracer imaging is illustrated in a recent dual-tracer PET study of patients with ischemic stroke and ipsilateral carotid stenosis, which revealed that uptake of $^{18}$F-FDG (in dual-tracer PET study of patients with ischemic stroke and ipsilateral carotid bifurcations and $^{18}$F-FDG was distributed more evenly throughout arteries (Fig. 1) (13)). This differential uptake may reflect the distinct roles of inflammation and calcification in plaque development and vulnerability.

Several radiotracers that were initially developed for other applications also bind to target molecules on inflammatory cells and could be of value for imaging cardiovascular inflammation. Radiotracers with preexisting human studies, including those with U.S. Food and Drug Administration (FDA) approval for other indications, expedite the process for testing and potential clinical development.

These tracers had 100% sensitivity and a 100% positive predictive value in identifying patients with recent stroke or transient ischemic attack. Although these results are promising, it is not known whether the same approach can be used to identify the plaques at risk for future events. $^{11}$C-PK11195 PET has also demonstrated increased uptake in patients with large-vessel vasculitis (Fig. 2) (18). However, in another study of patients with stroke or vasculitis, other TSPO tracers ($^{11}$C-PBR28 and $^{18}$F-PBR06) did not produce significant in vivo signals (19). Of note, there is also considerable uptake of $^{11}$C-PBR28 in normal myocardium (21), which may limit its utility for imaging of cardiac inflammation.

Another TSPO-targeting tracer, $^{18}$F-GE180, has shown greater binding to M1-polarized macrophages than M2-polarized macrophages (20). In a murine study of MI, an early increase in $^{18}$F-GE180 uptake was observed at the site of infarct, with signals returning to the reference range after 4 wk, suggesting that the TSPO signal may reflect early post-MI inflammation (20). Importantly, global $^{18}$F-GE180 uptake at 1 wk predicted a future reduction in left ventricular ejection fraction. Small-scale human studies have confirmed the early increase in post-MI $^{18}$F-GE180 signal (20), and additional clinical studies are being conducted to evaluate this tracer for imaging cardiac sarcoidosis (NCT03561025). Unresolved issues regarding TSPO-targeted imaging of cardiovascular inflammation include noninflammatory cell expression of TSPO, the selectivity of the

Mitochondrial Translocator Protein (TSPO) Imaging

TSPO, a ubiquitous mitochondrial protein involved in a large number of cellular functions, including mitochondrial cholesterol transport and steroid hormone biosynthesis (16), is classically used as a marker of neuroinflammation. More recently, expression of TSPO in activated macrophages has motivated the evaluation of radiotracers targeting TSPO for imaging of cardiovascular inflammation in pathologies such as MI, myocarditis, sarcoidosis, atherosclerosis, and vasculitis. Examples of such radiotracers include 1-[2-chlorophenyl]-N-methyl-N[1-methyl-propyl]-3-isooquinoline carboxamide ($^{11}$C-PK11195) (17,18), N-acetyl-N-(2-[15]C-methoxybenzyl)-2-phenoxoxy-5-pyridinamine ($^{11}$C-PBR28) (19), $^{18}$F-N-fluoroacetacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxa

FIGURE 1. Differential distributions of inflammation and microcalcification in symptomatic carotid atheroma. Axial noncontrast CT (A), $^{18}$F-FDG PET/CT (B), $^{18}$F-FDG PET (C), CT angiography (D), $^{18}$F-NaF PET/CT (E), and $^{18}$F-NaF PET (F) show symptomatic right carotid artery (purple arrow) and asymptomatic left carotid artery (green arrow); sagittal $^{18}$F-FDG PET/CT (G) shows diffuse uptake in symptomatic carotid artery (arrows); and $^{18}$F-NaF PET (H) shows focal uptake in symptomatic carotid artery (arrow). (Reprinted from (13)).
tracers for different TSPO isofoms and multimers, and whether the magnitude of radiotracer signals is sufficient for clinical applications. In addition, interpretation of human studies is affected by a genetic polymorphism that influences tissue binding of certain TSPO radiotracers (22). Addressing these limitations will be necessary for routine use of TSPO-targeted imaging in clinical cardiovascular medicine.

**Somatostatin Receptor (SSTR) Imaging**

SSTR-targeted radiotracers have been classically used as neuroendocrine tumor imaging agents. There are 5 subtypes of SSTRs, with peripheral blood mononuclear cells expressing mainly SSTR subtypes 2 and 3. Macrophages mainly express SSTR subtype 2, with the highest expression detected in inflammatory M1 macrophages (23), whereas lymphocytes express mainly SSTR subtype 3 (24). There are important variations in receptor subtype affinity profiles between different SSTR-targeted tracers (25). The 68Ga-labeled somatostatin analog 68Ga-DOTATATE binds to SSTR2 with high affinity and selectivity relative to other SSTRs (25). In a prospective study of patients with cardiovascular disease, 68Ga-DOTATATE uptake in atherosclerotic plaques was shown to be macrophage-specific and discriminate between culprit and nonculprit plaques in patients with acute coronary syndrome and cerebrovascular accidents (23). Furthermore, the 68Ga-DOTATATE signal in plaques was associated with high-risk coronary CT features (e.g., spotty calcification, low attenuation, positive remodeling) and correlated with Framingham risk score (r = 0.53, P < 0.0001) and 18F-FDG uptake (r = 0.73, P < 0.0001) (23). In a separate study of sarcoidosis patients, PET imaging with 68Ga-DOTATOC, which has a high affinity for SSTR2 and moderate affinity for SSTR5, performed better than conventional 67Ga-scintigraphy for the detection of sarcoidosis lesions (26). However, whereas basal uptake of 68Ga-DOTATOC in the heart was minimal, none of the patients in the study had active cardiac sarcoidosis. As such, additional information is needed to establish the value of SSTR2-targeted radiotracers for imaging of cardiovascular inflammation. In this regard, potential impediments to clinical applications of 68Ga-DOTATATE for imaging of cardiovascular inflammation include the modest level of increase in SSTR2 expression in culprit atherosclerotic plaques (23).

**Chemokine Receptor Imaging**

Chemokines are a family of small chemoattractant proteins that play key roles in leukocyte recruitment and activation through binding to chemokine receptors. Radiotracers that target chemokine receptors such as CXCR4 and CCR2 have recently emerged as promising agents for imaging inflammation (27,28). 68Ga-pentixafor was initially developed for CXCR4 imaging in cancer (29). Recent studies on mice have shown that post-MI 68Ga-pentixafor uptake is increased in parallel with leukocyte infiltration (30). In patients with acute MI, PET imaging showed variable patterns of 68Ga-pentixafor uptake (30). Furthermore, whereas there was no correlation with summed rest perfusion defect score, late gadolinium enhancement, or edema score by MRI, the 68Ga-pentixafor signal correlated with a combination of infarct size and time of imaging after reperfusion (r_{multiple} = 0.73, P = 0.03) (30). Examples of other radiotracers that target chemokine receptors include 68Ga- and 64Cu-DOTA-ECL1i (31,32), which target CCR2, and 64Cu-viral macrophage inflammatory protein-II (64Cu-DOTA-vMP-II), which targets a broad range of chemokine receptors (33). CCR2 is upregulated on inflammatory cells after myocardial injury (34) and in abdominal aortic aneurysms (AAAs) (32). CCR2-targeted imaging with 64Cu-DOTA-ECL1i is undergoing clinical evaluation in patients with AAAs (NCT04592991). This study follows promising results with ECL1i-based tracers in rodent studies that established the ability to detect CCR2+ monocytes and macrophages within post-MI hearts (68Ga-DOTA-ECL1i) (31) and demonstrated greater radiotracer uptake in AAAs that subsequently ruptured (64Cu-DOTA-ECL1i) (32).

**MMP Imaging**

Inflammatory cells are a major source of proteases, and MMP activation contributes to atherosclerotic plaque vulnerability, adverse left ventricular remodeling after MI, and AAA development and rupture. MMP-targeted radiotracers that target a broad range of MMPs, including 111In-RP782, 99mTc-RP805, and 99mTc-RYM1, have shown promise in preclinical studies of post-MI remodeling, atherosclerosis, calcific aortic valve disease, and aortic aneurysms (35–40). Tissue uptake of these tracers correlates well with both MMP activity and CD68 macrophage expression in murine models of atherosclerosis (35,41), calcific aortic valve disease (39), and aneurysm (40). Accordingly, MMP-targeted imaging may indirectly inform on the extent of cardiovascular inflammation. For instance, in a murine model of angiotensin-II–induced AAA, aortic 99mTc-RP805 signals on small-animal SPECT/CT images correlated with MMP activity quantified by zymography (r = 0.83, P < 0.001), as well as CD68 messenger RNA expression, a marker of monocytes and macrophages (r = 0.89, P < 0.0001) (40). Importantly, the MMP signal at 1 wk after angiotensin-II infusion correlated with AAA size at 4 wk (r = 0.53, P < 0.01), highlighting the potential of MMP-targeted imaging for AAA risk stratification. 99mTc-RYM1, which has a fast blood clearance, allows for imaging at 1 h after tracer injection and can similarly detect aortic MMP activity in murine models of aneurysm (Fig. 3) (38). Clinical studies with these MMP-targeted radiotracers are expected soon. The relative effectiveness of these broad-spectrum tracers as compared with emerging tracers that target specific members of the MMP family (e.g., MMP-12) remains to be determined (42).

**T-Cell Imaging**

Different lymphocyte subsets play distinct roles in inflammation. For instance, CD4+ T lymphocytes can activate and recruit other immune cells, whereas CD8+ T cells can mediate cell killing via release of intracellular granzymes (43). Several novel radiotracers that are in early stages of development for oncologic applications can potentially detect T-cell infiltration and may be valuable in cardiovascular applications such as myocarditis or sarcoidosis. Examples of these radiotracers include 89Zr-desferroxamine (DFO)-anti-CD3, which targets all types of T cells (44), 89Zr-DFO-CD4 (45), and 89Zr-DFO-CD8a (45). Future studies should address the value of these and related imaging agents in the diagnosis and management of inflammatory cardiovascular disease.

**RADIOTRACERS FOR THROMBOSIS IMAGING**

Thrombosis plays a central role in the pathogenesis of multiple disabling diseases, including MI, stroke, and pulmonary embolism. Detection and localization of the primary thrombus and any secondary emboli are often critically important for diagnosis and treatment. As such, there has been considerable interest in the development of nuclear imaging techniques that could potentially provide sensitive and specific whole-body detection of thrombi.

**Fibrin Imaging**

Fibrin is the end-product of the coagulation cascade and is one of the most widely pursued targets of radiotracers for thrombus
imaging. As fibrin is present in developing and mature thrombi, and absent from circulating blood, specific detection relies on target-selective binding to distinguish it from fibrinogen, its similar, widely circulating precursor (46). Early fibrin-targeted molecular diagnostic procedures were performed with radiolabeled fibrinogen and later with radiolabeled antifibrin antibodies and antibody fragments. However, the field has since moved in the direction of fibrin-binding peptides, given their generally more favorable production, binding, and pharmacokinetic characteristics. Numerous fibrin-binding peptides have been developed and labeled for MR, PET, PET/MR, and SPECT imaging in preclinical thrombosis models (46–48). One such fibrin-targeted PET radiotracer, 64Cu-labeled fibrin-binding probe 8 (64Cu-FBP8), demonstrated highly accurate carotid artery and femoral vein thrombus detection in rats (97.6%; 95% CI, 92–100) (49). Moreover, the 64Cu-FBP8 signal provided insight into clot chronicity and composition, as 64Cu-FBP8 uptake was greater in younger than older clots in both arteries and veins. This result was corroborated by quantitative histopathology, which demonstrated an age-dependent reduction in thrombus fibrin content. 64Cu-FBP8 is undergoing clinical investigation to evaluate its effectiveness for left atrial appendage thrombus imaging (NCT03830320) (50). Initial results demonstrated that 64Cu-FBP8 is metabolically stable and undergoes rapid bloodstream clearance. In addition, maximum SUVs in left atrial appendages were significantly greater in patients with transesophageal imaging–confirmed left atrial appendage thrombi than those with negative imaging results (median, 4.0 vs. 2.3 [interquartile range, 6.0–10.0 vs. 0.4–6.0] vs. median, 3.0–6.0 vs. median, 2.3 [interquartile range, 2.1–2.5]; P < 0.0001). 64Cu-FBP8 is also being evaluated clinically for the detection of deep venous thrombosis and pulmonary embolism (NCT04022915).

Activated Platelet Imaging

Similar to fibrin, activated platelets are essentially present in large numbers only in developing thrombi and healing wounds and are thus attractive targets for acute thrombus imaging. The most common target on activated platelets is glycoprotein IIb/IIIa, a heterodimeric membrane receptor that, when activated, binds to von Willebrand factor and to its primary ligand, fibrinogen, to mediate platelet aggregation and aggregation (51). 99mTc-aptcide is an early SPECT imaging agent targeting glycoprotein IIb/IIIa that was approved by the FDA for detection of acute deep venous thrombosis. However, enthusiasm was ultimately tempered by the fact that it was not particularly effective for detecting pulmonary embolism (52). 18F-glycoprotein 1 (GP1) is an 18F-labeled derivative of the small-molecule glycoprotein IIb/IIIa antagonist elarofiban (53–55). The binding of 18F-GP1 to glycoprotein IIb/IIIa is highly specific and appears to be minimally affected by aspirin or heparin treatment (55). In preliminary clinical evaluations, 18F-GP1 demonstrated the ability to identify thrombotic lesions in patients with acute deep venous thrombosis or pulmonary embolism (53), acute arterial thrombi (54), bioprosthetic valve thrombi (56), left atrial appendage thrombi (56), jugular vein thrombi (56), and left ventricular assist device thrombi (Fig. 4) (56). However, 18F-GP1’s vessel-level detection rate of pulmonary embolism was significantly lower than that for deep venous thrombosis (60% vs. 89%; P < 0.001), a finding that may relate to lower levels of activated platelets in older, embolic thrombi or inhibition of platelet activation in the setting of large pulmonary embolism (53). Further evaluation of 18F-GP1 in various clinical settings, including acute deep venous thrombosis (NCT04156230) and bioprosthetic valve thrombosis (NCT04073875), is in progress.

Factor XIIIa Imaging

Factor XIIIa is an activated enzyme that crosslinks fibrin during the terminal step of the coagulation pathway and is thus another molecular target for imaging of thrombus (57). Several factor XIIIa–targeted radiotracers based on α3-antiplasmin, a substrate of factor XIIIa in the transglutaminase crosslinking reaction, have been evaluated in preclinical models. 18F-ENC2015 is a fluorescent and positron-emitting factor XIIIa-targeting probe that has demonstrated rapid, selective binding to thrombi in initial preclinical carotid artery thrombosis models (58). Ultimately, information on the sensitivity of ENC2015 and other tracers to small foci of thrombosis, their effectiveness in the presence of antplatelet and anticoagulant agents, and their ability to differentiate between active and chronic thrombi will be key to their acceptance as clinical tools.

RADIOTRACERS FOR CARDIOVASCULAR FIBROSIS IMAGING

Tissue fibrosis is a consequence of dysregulated repair responses to various types of injury. Excessive extracellular matrix deposition (mainly collagen) leading to interstitial or replacement fibrosis is the result of dysregulated fibroblast activation and myofibroblast transformation. Inflammation, activation of transforming growth factor β, focal secretion of other cytokines, and MMP activation drive this process (59). In the myocardium, fibrosis can lead to cardiac dysfunction and serve as a nidus for arrhythmias (60). The burden of myocardial fibrosis related to nonischemic cardiomyopathy and myocardial injuries from MI, cytotoxic chemotherapy or radiation, and inflammatory or immune-mediated conditions (e.g., myocarditis) has

FIGURE 3. 99mTc-RYM1 imaging of AAA. (A) Comparison of blood clearance of 99mTc-RYM1 and 99mTc-RP805 in mice. (B) Examples of fused 99mTc-RYM1 SPECT/CT images of AAA in angiotensin II-infused mice at wk after aneurysm induction. Arrows point to tracer uptake in AAA on axial (left), coronal (middle), and sagittal (right) views. (C) Aortic 99mTc-RYM1 signal in vivo correlates well with MMP activity quantified by ex vivo zymography. %ID = percentage injected dose; AU = arbitrary units; cpv = counts per voxel; p.i. = after injection. (Reprinted from (38).)
The efficacy of therapeutics targeting and quantifying the presence of active collagen turnover is crucial in the development of noninvasive means to monitor cardiovascular disease. Molecular imaging may provide a novel approach to monitor collagen turnover, which has been shown to be associated with several cardiovascular diseases, including acute coronary syndromes and atherosclerosis. However, the spatial resolution of current nuclear imaging modalities is limited, which hinders the detection and quantification of collagen turnover.

In one study, the uptake of 68Ga-FAPI in left ventricular myocardium has shown a significant correlation with the presence of coronary artery disease (r² = 0.16, P = 0.03) (Fig. 5). Another study demonstrated that left ventricular 68Ga-FAPI uptake correlated with the presence of cardiovascular risk factors such as overweight status (odds ratio, 2.6; P = 0.023), type 2 diabetes (odds ratio, 2.9; P = 0.041), and histories of platinum-based chemotherapy (odds ratio, 3.0; P = 0.034) and chest radiation (odds ratio, 3.5; P = 0.024) (68). Finally, a retrospective analysis of 68Ga-FAPI PET/CT images obtained for noncardiovascular indications showed that focal arterial uptake of the tracer correlated negatively with calcification (r = −0.27, P < 0.01) (69). Several ongoing trials seek to establish the role of FAPI imaging to detect post-MI cardiac fibrosis (NCT04803864, NCT04723953).

### Extracellular Matrix Imaging

Collagens, especially types I and III, constitute the bulk of fibrotic tissue and are typically used as targets for imaging fibrosis. Several SPECT and PET tracers that target different types of collagen, including 99mTc-collagelin (70), 68Ga-collagelin (71), 64Cu-collagen-binding probe (CBP) 7 (72), and 64Cu-CBP8 (73), have been used in animal and human studies to evaluate fibrosis. However, there are only a few reports of using these tracers in the cardiovascular system. For instance, in a rat model of MI, 99mTc-collagelin tracer uptake occurred in areas of histologically confirmed fibrosis (70). Additional studies are needed to establish the utility of these radiotracers for cardiovascular fibrosis imaging. Given the role of MMPs in extracellular matrix remodeling, MMP-targeted imaging may also provide valuable information on fibrotic processes in cardiovascular disease.

### 18F-NAF PET IMAGING OF CARDIOVASCULAR CALCIFICATION

Ectopic calcification in arteries and cardiac valves is driven by osteoblastic differentiation of vascular smooth muscle cells and valvular interstitial cells. The role of calcification in cardiovascular disease...
pathology is complex and context-dependent. In coronary arteries, microcalcification is considered a classic feature of vulnerable plaque that is prone to rupture, whereas macrocalcification may be associated with plaque stability (74). In valvular disease, calcification directly contributes to the development of valvular dysfunction. Accordingly, there is potential value in detecting calcification as a diagnostic and possibly prognostic tool in cardiovascular disease. Although CT can detect established, macroscopic foci of calcification, \( ^{18} \text{F}-\text{NaF} \) PET has recently emerged as a promising tool to detect the process of calcification. Fluoride binds to hydroxapatite in calcified tissue through an exchange process with hydroxyl groups. Microcalcifications have greater surface area per mass for \( ^{18} \text{F}-\text{NaF} \) binding than do macrocalcifications and thus tend to produce more intense signals (74). Recent studies have shown greater uptake of \( ^{18} \text{F}-\text{NaF} \) in culprit plaques after recent acute coronary syndrome (75), and a post hoc analysis of several observational studies showed that global estimates of coronary \( ^{18} \text{F}-\text{NaF} \) signals in patients with known coronary artery disease may predict future risks of MI (76). Ongoing studies such as the Prediction of Recurrent Events with \( ^{18} \text{F}-\text{Fluoride} \) (PREFFIR, NCT02278211) should further clarify the role of \( ^{18} \text{F}-\text{NaF} \) PET imaging in determining risk for future cardiovascular events.

\( ^{18} \text{F}-\text{NaF} \) PET has also demonstrated potential clinical utility for imaging of valvular calcification. In patients with calcific aortic valve stenosis and mitral annular calcification, valvular \( ^{18} \text{F}-\text{NaF} \) PET signals have been shown to correlate with the severity of calcification detected by CT. Moreover, \( ^{18} \text{F}-\text{NaF} \) PET signals on valves have been shown to predict the development of macroscopic calcification several years before detection on CT (77–79), and greater \( ^{18} \text{F}-\text{NaF} \) PET signals have been linked to faster progression of calcification, although not independently of baseline CT-derived calcium scoring (77). Several recent comprehensive reviews provide more detailed discussions of the potential of \( ^{18} \text{F}-\text{NaF} \) PET for studying cardiovascular pathophysiology and assessing vascular (carotid and coronary artery atherosclerosis, abdominal aortic aneurism) and valvular diseases and their responses to therapy (80,81).

**RADIOTRACERS FOR CARDIAC AMYLOIDOSIS IMAGING**

Amyloidosis affects multiple organ systems through extracellular accumulation of amyloid fibrils. These insoluble fibrils form as the result of misfolding and aggregation of various precursor proteins, many of which are normal constituents of plasma. Cardiac involvement is common in the 2 most prevalent forms of amyloidosis, transthyretin amyloidosis (ATTR) and immunoglobulin light-chain amyloidosis (AL). Nuclear imaging has emerged to play a key role in the diagnosis of ATTR and AL cardiomyopathies. Early and accurate detection of these conditions is important given the availability of effective but time-sensitive treatments.

ATTR cardiomyopathy can be diagnosed noninvasively through semiquantitative analysis of planar or SPECT images using \( ^{99m} \text{Tc} \)-labeled bisphosphonate derivatives that were initially developed for bone imaging. \( ^{99m} \text{Tc} \)-pyrophosphate is used most in the United States, whereas \( ^{99m} \text{Tc} \)-hydroxymethylene diphosphonate (\( ^{99m} \text{Tc} \)-HMDP) and \( ^{99m} \text{Tc} \)-3,3-diphenyl-1,2-propanedicarboxylic acid (\( ^{99m} \text{Tc} \)-DTP) are more commonly used in Europe. These radiotracers are generally considered to have similar diagnostic performance, although direct comparisons are limited. In a multicenter study of patients with suspected amyloid cardiomyopathy, pooled scintigraphy data using these 3 radiotracers demonstrated that the presence of myocardial radiotracer uptake was more than 99% sensitive and 86% specific for histologically confirmed ATTR, with false-positives related almost exclusively to low-level uptake in the setting of AL (82). Notably, the combination of grade 2 and 3 scintigraphic uptake and negative urine or serum monoclonal protein analysis had a specificity and positive predictive value for ATTR of 100%.

PET radiotracers that were initially developed for imaging of brain amyloid plaques related to Alzheimer disease have been evaluated for the detection of cardiac amyloidosis. In initial studies, \( ^{11} \text{C} \)-Pittsburgh compound B (83), \( ^{18} \text{F} \)-florbetapir (84), and \( ^{18} \text{F} \)-florbetaben (85) have demonstrated potential diagnostic utility for detecting both AL and ATTR cardiomyopathies. \( ^{18} \text{F} \)-flumetorol, an \( ^{18} \text{F} \)-based analog of \( ^{11} \text{C} \)-Pittsburgh compound B, has also been studied for cardiac amyloid imaging, although more recent work has raised questions about its sensitivity (86). \( ^{18} \text{F} \)-florbetapir and \( ^{18} \text{F} \)-florbetaben are currently undergoing evaluation in clinical trials. In all, quantitative PET-based approaches for imaging cardiac amyloidosis may provide additional benefits beyond diagnosis, such as correlating amyloid burden with prognosis (83) or responses to novel disease-modifying treatments (85). Because of the short half-life of \( ^{11} \text{C} \), which restricts its use to centers with on-site cyclotrons, \( ^{18} \text{F} \)-based agents have greater potential for large-scale clinical use.

**CONCLUSIONS AND FUTURE PERSPECTIVES**

Molecular imaging is anticipated to play an increasingly more prominent role in clinical cardiovascular medicine. Although many radiotracers with potential cardiovascular applications have been evaluated in preclinical and clinical studies, only a select few to date have advanced to mainstream clinical usage. Aside from the technical and performance-related requirements of radiotracer development, clinical implementation requires clear definition of their diagnostic roles and demonstration of added value beyond existing clinical imaging techniques. Moreover, the clinical market for emerging radiotracers must be large enough to justify their initial research and development costs, an issue that may be addressed by targeting key, common biologic processes rather than specific diseases. Although these factors seemingly pose formidable barriers, the demand for new radiotracers is increasing because of evolving trends in medicine toward molecular characterization and personalized therapies. Technical advances in areas such as radiotracer chemistry, instrumentation, and data analysis are facilitating radiotracer development to address the numerous unmet clinical needs.

**REFERENCES**


70. Vol. 63 No. 7	July 2022